SEC FIlings Archives - Page 5 of 19

06 Feb

SEC FIlings

Current report

February 6, 2023
Posted by Jitendra

03 Feb

SEC FIlings

Prospectus [Rule 424(b)(3)]

February 3, 2023
Posted by Jitendra

03 Feb

SEC FIlings

Prospectus [Rule 424(b)(3)]

February 3, 2023
Posted by Jitendra

03 Feb

SEC FIlings

Prospectus [Rule 424(b)(3)]

February 3, 2023
Posted by Jitendra

02 Feb

SEC FIlings

Current report

February 2, 2023
Posted by Jitendra

02 Feb

SEC FIlings

Current report

February 2, 2023
Posted by Jitendra

30 Jan

SEC FIlings

Prospectus [Rule 424(b)(3)]

January 30, 2023
Posted by Ulisses

30 Jan

SEC FIlings

Prospectus [Rule 424(b)(3)]

January 30, 2023
Posted by Ulisses

30 Jan

SEC FIlings

Prospectus [Rule 424(b)(3)]

January 30, 2023
Posted by Ulisses

30 Jan

SEC FIlings

Current report

January 30, 2023
Posted by Ulisses

SEC FIlings

Current report

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Current report

Current report

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Current report

test according

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information

Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists